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Abstract
Background: Anaplastic thyroid carcinoma (ATC) is among the most aggressive human malignancies. It is
associated with a high rate of local recurrence and with poor prognosis.
Methods: We retrospectively reviewed 44 consecutive patients treated between 1996 and 2010 at Leon Berard
Cancer Centre, Lyon, France. The combined treatment strategy derived from the one developed at the Institut
Gustave Roussy included total thyroidectomy and cervical lymph-node dissection, when feasible, combined with 2
cycles of doxorubicin (60 mg/m2) and cisplatin (100 mg/m2) Q3W, hyperfractionated (1.2 Gy twice daily) radiation
to the neck and upper mediastinum (46-50 Gy), and then four cycles of doxorubicin-cisplatin.
Results: Thirty-five patients received the three-phase combined treatment. Complete response after treatment was
achieved in 14/44 patients (31.8%). Eight patients had a partial response (18.2%). Twenty-two (50%) had progressive
disease. All patients with metastases at diagnosis died shortly afterwards. Thirteen patients are still alive. The
median survival of the entire population was 8 months.
Conclusion: Despite the ultimately dismal prognosis of ATC, multimodality treatment significantly improves local
control and appears to afford long-term survival in some patients. There is active ongoing research, and results
obtained with new targeted systemic treatment appear encouraging.
Background
Anaplastic thyroid carcinoma is an uncommon malig-
nancy that accounts for only 2 to 5% of all thyroid can-
cers. It is one of the most aggressive human malignant
tumors, in contrast to differentiated thyroid malignan-
cies. Patients are typically elderly, with the majority
older than 60 years [1,2]. At the time of diagnosis,
approximately 40% of patients have distant metastases,
80% of them in the lung. Despite different treatment
approaches, ATC grows rapidly, invades adjacent tissues,
and most patients die due to uncontrolled local tumor
invasion causing suffocation [3,4]. The treatment
options for ATC include surgery, chemotherapy and
radiotherapy, but all of these, especially if used alone,
generally fail to control local disease.
Multimodal therapy combining surgery, chemotherapy
and radiation therapy, can achieve better results in
avoiding death from local invasion and suffocation and
improving survival in some patients [5,6]. Nevertheless,
t h ea g g r e s s i v en a t u r ea n dr a r i t yo fA T Cm a k ei td i f f i c u l t
to compare patient outcomes, especially in studies with
small cohorts and short follow-up. A standardized success-
ful protocol remains to be established and the optimal
sequence of multimodal therapy is still debated [7]. In
France, all cancer centers treating patients with anaplastic
thyroid carcinomas use a standard treatment called the
“IGR protocol” named after the Institut Gustave Roussy
where it was proposed and first published [6].
Here, we retrospectively report the clinical outcome of
all ATC patients treated in our Institution between 1996
and 2010.
Methods
The clinical records of all patients with anaplastic thyr-
oid carcinoma referred to the Centre Leon Berard
between 1996 and 2010 were reviewed. Data were
extracted for all patients with a confirmed diagnosis of
anaplastic thyroid cancer.
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or cytological (fine-needle biopsy) features and was con-
firmed, when necessary, by immunochemical staining.
All patients underwent computed tomography (CT) of
the neck and chest before or after thyroid surgery.
Tumor staging was determined according to the TNM
classification proposed by the American Joint Commit-
tee on Cancer (7th edition of TNM AJCC)[8]. “T”
describes the size and location of the tumor. All ana-
plastic carcinomas are considered T4 tumors. T4a is for
intrathyroidal anaplastic carcinomas–surgically resect-
able. T4b is for extrathyroidal anaplastic carcinomas–
surgically unresectable. “N” refers to regional lymph
node involvement (central, lateral cervical, and upper
compartment).
No corresponds to no regional lymph node metastasis.
N1, used to denote regional lymph node metastases,
subdivides into N1a indicating metastases to level VI
(pretracheal, paratracheal, and prelaryngeal lymph
nodes), and N1b indicating unilateral or bilateral metas-
tases to cervical or superior mediastinal lymph nodes.
M1 is used to designate distant metastases. For thyroid
cancer, this staging system differs with the tumor cell
type: all anaplastic carcinomas are considered stage IV.
Surgical removal of the thyroid and cervical nodes,
when possible, was generally the first step of the treat-
ment. The surgical procedure was identified as total
thyroidectomy, near total Thyroidectomy, biopsy or
debulking. Total thyroidectomy denoted the removal of
both lobes and the isthmus. Resection of one entire
lobe, the isthmus and a portion of the other lobe was
considered near total thyroidectomy. Any surgery less
than resection of an entire lobe was considered a biopsy.
Debulking was defined as a tumor reduction of more
than 90%. The presence of residual tumor after surgery
was evaluated by using the “R” classification with R0
corresponding to no residual tumor, R1 to microscopic
residual tumor and R2 to macroscopic residual tumor.
Radiotherapy (RT) was administered postoperatively.
Hyperfractionated (two fractions of 1.2 Gy twice daily)
or conventional radiation was used. Conventional radio-
therapy was used instead hyper fractionated radiother-
apy in poor general status patients. The RT volume was
confined to the whole anterior half of the neck and
upper 5 cm of the mediastinum. Radiation was achieved
using two opposed antero-posterior fields. The total
dose was estimated to vary from 46 to 50 Gy and was
delivered over about 5 weeks. Concerning chemother-
apy, two drugs, doxorubicin (50-60 mg/m2/d) and cis-
platin (100 mg/m2/d) were used as a one-day treatment,
repeated every 3 weeks.
Two cycles were administered before irradiation and 4
cycles afterwards. The time interval between chemother-
apy and beginning/end of radiotherapy was 10 days.
Carboplatine was used to replace cisplatin in combination
with doxorubicin for patients with renal insufficiency.
Patients received GCSF and some had EPO primary pro-
phylaxis. They also had nutritional support during radio-
therapy. Evaluation of tumor response was performed
after the first two courses of chemotherapy, after thyroid
irradiation, one month after the end of treatment, then
every three months. Tumor measurement techniques
included physical examination and CT scan. The Response
Evaluation Criteria in Solid Tumors (RECIST) criteria
were used to assess response. Complete remission (CR) is
defined as the complete disappearance of all clinically and
radiographically demonstrable tumors and partial remis-
sion (PR) as a 30% decrease in the sum of the largest dia-
meters of all measurable lesions. Progressive disease is
defined as an increase of at least 20% in the sum of the lar-
gest diameters of all measurable lesions. Stable disease is
the absence of CR or PR without any disease progression.
Survival was measured from initiation of treatment.
Kaplan Meier was used for statistical analysis.
The prognostic factors relatives to the patient were
WHO performance status, age, sex, maximum diameter of
tumor ≥ 5 cm, existence of acute symptoms at diagnosis,
distant metastases, tracheal infiltration and WBC count
(≥10,000/mm3). Impact of the treatment (type of surgery,
residual disease after surgery, type of radiotherapy and
chemotherapy, complete treatment) was also studied.
Toxicity was evaluated in accordance with the National
Cancer Institute Common Toxicity Criteria (NCI-CTC).
Results
Patient characteristics
During the time interval considered, 44 patients were
referred to our institution (table 1). The majority were
women (1.4:1). The age range was 44-80 years. A clini-
cal history of pre-existing thyroid disease (thyroid
nodules or goiter) was found in 10 patients (22%). The
coincidental presence of a well-differentiated thyroid
carcinoma was noted on examination of surgically
resected ATC in 8 patients. Five of these had papillary
carcinoma and 3 had follicular carcinoma.
Thirty-eight patients (84%) presented with complaints
of a sudden increase of a thyroid mass, 32 (71%) with
signs of local compression (dyspnea, dysphagia, dyspho-
nia, and cervical pain).
Twelve patients (26%) reported a weight loss. The
WHO performance status was 0 or 1 for 38 patients
and ≥2 for 6 patients. Clinicopathological factors rela-
tives to patients are presented in tables 1.
Tumour characteristics
Different morphological patterns of ATC were identi-
fied: giant, spindle or squamoid cell carcinomas, some-
times with a mixed pattern [8]. Large-cell and mixed
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logical patterns. At diagnosis, tracheal infiltration was
observed in 13 patients (30%). Thirty-nine patients pre-
sented with a tumor ≥ 5 cm. Distant metastases, most
commonly located in the lungs, were found at the time
of diagnosis in 21 patients, and 11 had more than 3 fac-
tors of poor prognosis.
Treatment
The treatments are described in table 2.
Surgery
Of the 44 patients studied, 28 had a total thyroidectomy,
7 had a near total thyroidectomy and 9 had debulking
surgery. Tumor resection was complete in only 8
patients (18.2%) whereas 9 (20.5%) had microscopic resi-
dual disease (resection R1) and 25 (56.8%) macroscopic
residual disease (R2). Lymph node involvement was
found in 22 patients. Nineteen patients had node resec-
tion. After surgery, 10 patients encountered unilateral
vocal cord paralysis, 4 patients had hemorrhage in surgi-
cal site and 2 patients presented hypocalcaemia despite
of calcium supplement. No patient required tracheot-
omy during treatment.
Post-operative treatment
Thirty-nine patients received radiation to the thyroid
area. Hyperfractionated radiotherapy was used in 34
patients whereas 5 had conventional radiation.
Thirty-eight patients (80%) received chemotherapy;
thirty-three received a combination of doxorubicin and
cisplatin, three received doxorubicin and carboplatin,
one received doxorubicin alone and one received pacli-
taxel. Among the 35 patients who received the three-
phase combined treatment, 14 (41%) received the full
six scheduled cycles of chemotherapy. Treatment was
stopped because of toxicity in 4 patients.
Eight patients received a second line of chemotherapy
after progression. Three received paclitaxel, three
received capecitabine, one received vinorelbine and one
had holoxan-vepeside.
Tumor response and survival
A tt h ee n do ft r e a t m e n t ,ac o m p l e t er e s p o n s e( C R )w a s
observed in 14 patients (31.8%) and a partial response in 8
patients (18%). The median survival of these responders
was 28.4 months; it was significantly different from that of
progressive patients (50%) which was 5.1 months. With a
median follow up of 7, 8 months (0,7, 160,6), 31 patients
died and the median OS was 8 months (6, 16,5). The med-
ian PFS was 6, 5 months (4,3, 12,5) (Figures 1 and 2).
Thirteen of the 44 treated patients are still alive, with
a median overall survival (OS) of 8 months and a
Table 1 Patient characteristics
Number of patients (%) 44
Median age at diagnosis (years) 65
(44-80)
Gender
Female 26 (59)
Male 18 (41)
Female/male ratio 1.4
Preexisting thyroid disease
Nodular goiter 10 (22.7)
Well-differentiated thyroid carcinoma 8 (18.1)
Clinical presentation
Enlarged thyroid mass 38 (86.3)
Signs of local compression (dyspnea, dysphagia, dysphonia,
and cervical pain).
32 (72.7)
Weight loss 12 (27.2)
Clinical extent of disease
Local (T4 N0 M0) 12 (27.2)
Regional (T4 N1 M0) 12 (27.2)
Distant (T4 N0 M1, T4 N1 M1) 20 (45.4)
Histology
Giant cells 19 (43.1)
Spindle cells 14 (31.8)
Mixed pattern 6 (13.6)
Not available 5 (11.3)
Table 2 Treatment
Type of treatment (%)
Surgery alone 2 (4.5)
Surgery + CT 3 (7)
Surgery + RT + CT 35 (79.5)
RT alone 2 (4.5)
Surgery + RT 2 (4.5)
Type of surgery
Total thyroidectomy 28 (63.6)
Near total thyroidectomy 7 (15.9)
Biopsy/Debulking 9 (20.4)
Residual disease after surgery
None 8 (18.1)
Microscopic residual disease 9 (20.4)
Macroscopic residual disease 25 (56.8)
Type of radiotherapy
Conventional 5 (11.3)
Hyperfractionated 34 (77.2)
Chemotherapy schedule
Doxorubicin+ cisplatin 33 (75)
Doxorubicin +carboplatin 3 (7)
Doxorubicin 1 (2.2)
Paclitaxel 1 (2.2)
Treatment response
Complete response 14 (31.8)
Partial response 8 (18.1)
Disease progression 22 (50)
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Median OS and PFS were significantly lower in the
patients undergoing palliative surgery (debulking) than
in those undergoing near-total or total thyroidectomy
(3.7 vs. 14.7 months respectively for OS, 3.7 vs. 10.6
months respectively for PFS). No significant difference
in median OS and PFS was seen between the patients
with local stage ATC and those with loco-regional or
metastatic stage disease. Significantly better median OS
and PFS rates were reported in the patients who had 3
or less factors of poor prognosis than in those who had
more than 3 (14.7 vs. 4 months respectively for OS, 9
vs. 4 months respectively for PFS). We analyzed indivi-
dually clinicopathological factors relatives to patients
and treatment as prognostic factors presented in Figure
3 and 4.
Toxicity
The main toxicity was digestive, with 65% grade 3 and 4
nausea and vomiting during treatment.
Anemia and neutropenia were frequent among
patients receiving doxorubicin and cisplatin.
Grade 3 and 4 neutropenia was observed in 22.7% of
the patients, whereas grade 3 or 4 thrombocytopenia
was observed in 2.3%. The hematological toxicity was
secondarily reduced by the systematic administration of
G-CSF and erythropoietin. Weight loss was noted in
65% of the patients in spite of nutritional support during
radiotherapy. Finally, one patient had reversible renal
toxicity.
Discussion
Anaplastic thyroid carcinoma is a highly lethal cancer
with a spontaneous median survival of 4 to 12 months
from the time of diagnosis [4]. It represents less than
2% of all thyroid cancers but still accounts for up to
40% of thyroid cancer mortality [9,10].
The characteristics of the patients in our study were
similar to those described in the literature with an age
between the sixth and seventh decades. There was a
slight female to male predominance of 1.5 to 1. A large
percentage of patients already had distant metastases at
presentation. As in our study, the most common site of
metastases reported in a 50-year review by McIver et al.
[11] was the lung (42%), followed by bone (32%) and
brain (9%). Although the identification of histological
subtypes is an important part of the diagnosis of ATC,
histological characteristics do not provide prognostic or
predictive information regarding the patients’ disease
course or response to therapy. Because of a threat of
local or metastatic spread, therapeutic options in ATC
must combine local (cervical) and systemic treatments.
Single modality therapy has been shown to have limited
effect. Surgery or radiation, or chemotherapy alone
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Figure 1 Kaplan-Meier estimate of overall survival of all 44 patients with anaplastic thyroid carcinoma.
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Figure 2 Kaplan-Meier estimate of progression free survival of all 44 patients with anaplastic thyroid carcinoma.
Figure 3 Forest plot of hazard ratios for overall survival according to prognostic factors for 44 patients with anaplastic thyroid
carcinoma.
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recurrence and overall survival. In the study by Veness
et al. [12], 18 patients with ATC were treated at a single
center, with 9 having single modality treatment (6 had
radiation therapy, 3 had surgery, and 1 had chemother-
apy). Four of the six patients receiving radiation therapy
and two of the three patients undergoing surgery died
of uncontrolled local disease. Because of the disappoint-
ing results from single modality therapies, multimodality
therapy has progressively become the treatment of
choice in ATC, with surgery being the cornerstone of
patient management. Nearly all long-term survivors with
ATC have had surgery as part of their treatment. In a
retrospective review, Haigh et al. [13] describe five long-
term survivors treated with surgery followed by RT/che-
motherapy. More specifically, those patients who
underwent a potentially curative resection (8/26) had a
median survival of 43 months compared to 3 months
for those with a palliative resection. In the study by
Swaak-Kragten et al [14], patients who had R0/R1 resec-
tion and underwent protocol chemoradiation had a local
complete response rate of 89%, compared to only 3%
CR for patients receiving neither R0/R1 resection nor
protocol radiation. Complete locoregional response
resulted in longer median survival (7 months versus 3
months) and improved 1-year overall survival (32% ver-
sus 9%). Levendag et al. [15] has also described the
achievement of a CR as an important goal for treatment.
The above data confirm both the central role of surgery
as part of multimodality therapy for ATC and the
potential for long-term survival in a subset of patients.
Unfortunately, as seen in our study and as reported by
Haigh et al. [13], only a minority of patients can
undergo microscopic tumor resection at the time of
presentation.
The history of RT in the treatment of ATC has
evolved from high dose conventional RT to hyperfrac-
tionated RT administered in combination with continu-
ous chemotherapy. Since ATC is a rapidly dividing
tumor, hyper-fractionated RT minimizes the opportunity
for tumor cells to recover between treatments. Tennvall
et al. [5] have reported improvement in local control
with acceleration of hyperfractionated RT and concur-
rent chemotherapy. All 33 patients who achieved local
control had total resection, but 30 had microscopic resi-
dual disease. This supports the hypothesis that RT can
eradicate microscopic disease and improve survival
when given in effective doses and fractionation schemes.
Results published by Swaak-Kragten et al. [14] show
that the total radiation dose appears to be an important
Figure 4 Forest plot of hazard ratios for progression free survival according to prognostic factors for 44 patients with anaplastic
thyroid carcinoma.
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for patients treated with a total dose of > 40 Gy versus
only 1.7 months for those receiving < 40 Gy. In the
same study, the authors have added prophylactic lung
irradiation (PLI) in combination with low-dose doxoru-
bicin because of the very high percentage of patients
developing lung metastases in the course of their dis-
ease. This treatment had not been described in the lit-
erature for ATC before. Interestingly, of the 11 M0
patients treated only two subsequently developed lung
metastases; however, a significant benefit could not be
demonstrated due to the small number of patients trea-
ted and the lack of a control arm. Some chemotherapy
drugs have been tested to try to increase overall survival
in metastatic ATC patients. Results of a randomized
trial by Shimaoka et al. [16] comparing doxorubicin
alone to doxorubicin and cisplatin in 39 patients with
A T Ch a v es h o w nar e s p o n s er a t eo f5 %f o rt h es i n g l e
agent compared to 18% for the combination therapy.
The authors have concluded that combination therapy is
superior in terms of efficacy but this efficacy does not
balance the risk of increased toxicity. Ain et al. [17]
have employed paclitaxel in a phase II trial and have
demonstrated that treatment responders had a median
survival of 32 weeks compared to only 7 weeks in non-
responders. Multimodality treatments have demon-
strated efficacy in improving local tumor control in
some ATC patients and may increase survival in
patients with good performance status and without
renal or cardiac insufficiency or metastatic disease.
Unfortunately, most of the studies published were retro-
spective or were based on very small numbers of
patients [18,19]. In recent years, two important prospec-
tive trials have been published. First, Tennvall et al. [5]
have treated 55 consecutive patients with three different
treatment schedules, all containing surgery, hyperfractio-
nated radiotherapy and chemotherapy.
Despite this aggressive approach, overall survival was
poor with only 9% of patients surviving at 2 years. A
second study by the IGR team, published by De Crevoi-
sier et al. [6], has enrolled 30 patients (including 6 with
lung metastases) treated with surgery, chemotherapy
(doxorubicin and cisplatin) and hyperfractionated RT.
Results described a survival of 46% at 1 year and 27% at
3 years. These results are similar to ours (40% and 25%,
respectively) but higher than in most other studies
[5,18,19]. When considering our patients and those
from the IGR study we obtain a total of 74 French
patients treated with the same protocol. The results of
the 2 studies are equivalent, justifying the use of a com-
bined treatment in different cases of AT, principally for
non metastatic patients after thyroid surgery (either
complete or incomplete), whatever the lymph node sta-
tus (N0/N1). Secondly, for good PS metastatic patients
with limited metastatic lesions we would recommend a
multimodality treatment (chemoradiotherapy) and then
total thyroidectomy whenever feasible. It clearly appears
that the primary step of clinical management in ATC is
to identify potentially curable patients with ≤3 factors of
poor prognosis and to offer them multimodality treat-
ment to improve their chances of survival. Regarding
patients with more than 3 poor prognosis factors, we
should avoid aggressive therapy and offer them best
supportive care.
Regarding new antitumor therapies, ATC have poorly
benefited from recent progresses. Some have been tested
in ATC but results have been often disappointing. Tar-
geted agents directed against VEGF-R like axitinib (AG-
013736) or against BRAF and VEGF-R like sorafenib
(Nexavar
®) have been tested in phase II trials including
patients with anaplastic thyroid carcinoma [20,21]. One
response was obtained with axitinib and one stabiliza-
tion with sorafenib.
Vascular disrupting agents as Zybrestat
® (fosbretabu-
lin, combretastatin A4 phosphate (CA4P)) have been
evaluated in ATC because of their antiangiogenic and
cytotoxic activity. The promising results obtained in
vitro foreshadowed the clinical efficacy of the drug [22].
at the 35
th European Society of Medical Oncology
(ESMO) meeting, the preliminary results of a phase II-
III study of Zybrestat
® in combination with chemother-
apy in ATC were presented. In this study, 80 patients
(out of the 180 planned) were randomized to receive
Zybrestat
® (IV once a week) in combination with che-
motherapy (paclitaxel-carboplatin every 3 weeks) versus
chemotherapy alone. For the first time in ATC, the
median overall survival time was increased by the asso-
ciation (5.1 months versus 4.1 months for patients
receiving chemotherapy alone).
Conclusions
Despite the ultimately dismal prognosis of ATC, multi-
modality treatment significantly improves local control
and appears to achieve long-term survival in some
patients. Hopefully, active ongoing research should iden-
tify systemic treatments to be used in combination with
more conventional methods. A promising area of
research includes potential targeted treatment modalities
focusing on the genetic alterations found in ATC. For
example, p53 gene mutations commonly occur in ATC
and may explain the loss of control of cell proliferation
[23] but no treatment based on this abnormality has yet
emerged. Recently, a prospective randomized trial has
shown that CA4P (a reversible tubulin-binding vascular-
disrupting agent) induces a significant survival benefit
when used in combination with carboplatin and pacli-
taxel [24]. Other areas of active research involve angio-
genesis inhibitors and tyrosine kinase inhibitors [25].
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